Small cannabinoid biotech gets hit with cyberattack, clinical trial delays

Skye Bioscience has delayed a Phase I trial for its cannabinoid glaucoma treatment due to a cyberattack on its manufacturer.

The small San Diego biotech did not disclose which contract manufacturer it uses, but it did note the cyberattack has since been resolved. However, due to the attack, the third-party manufacturer had to delay its annual maintenance to August.